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Dear Editor,
Prostate secretory protein 94 (PSP94), also known as
β-microseminoprotein, is a product of the MSMB gene and
one of the most abundant proteins found in human seminal
plasma (Anklesaria et al., 2013). This small cysteine-rich
non-glycosylated protein is considered to be involved in
regulation of many biological processes including male
reproduction. It has been observed that PSP94 and its por-
cine homologue inhibit acrosomal reaction, sperm motility,
and maintain the sperm environment (Anahi Franchi et al.,
2008; Manaskova-Postlerova et al., 2011).
Despite of its possible role in reproduction, recently it has
been proposed its association with development of prostate
cancer (PC). It has been demonstrated that PSP94 sup-
presses tumor growth and reduces proliferation of some
cancer cells by inducing apoptosis. This action is suggested to
be regulated via binding to cell-surface receptors (Yang et al.,
1998; Annabi et al., 2006). Moreover, the large genome-wide
association studies showed that decreased expression of
PSP94 caused by the rs10993994 single nucleotide poly-
morphism is associated with an increased risk of developing
prostate cancer, suggesting a protective role of PSP94 in PC
incidence (Lou et al., 2009; FitzGerald et al., 2013).
Currently, the clinically validated test for PC diagnosis
relies on detection of serum level of prostate-speciﬁc antigen
(PSA, human kallikrein-3) using monoclonal antibody-based
ELISA kit but this examination, yet widely used, fails to
predict early stages of PC development and, in addition,
does not distinguish precisely between malign form of PC
and benign prostate hyperplasia. Due to lack of this speci-
ﬁcity many patients have to undergo unnecessary prostate
tissue biopsy (Lazzeri et al., 2012). To overcome this draw-
back, a larger set of PC biomarkers has been suggested to
improve early prediction of PC, to identify recurrent stages of
malignancy after the prostatectomy and treatment, and to
more precisely correlate serum-level oncomarkers with a
histological Gleason scoring. Therefore, novel and more
complex tools for improved PC diagnosis, including multi-
factorial biosensors or ELISA sets, are being required
(Mhatre et al., 2014).
Many studies have suggested that PSP94 could be a
useful biomarker for PC diagnosis and prognosis (Nam et al.,
2006; Reeves et al., 2006; Velonas et al., 2013). The esti-
mation of bound/free PSP94 has been suggested as an
independent prognostic marker following radical prostatec-
tomy that can predict time to recurrence of PC (Reeves et al.,
2006). The measurement of PSP94 levels was able to
identify patients with high-grade disease among a subset of
patients in whom tests of PSA or free/total PSA were least
informative (Nam et al., 2006; Mhatre et al., 2014).
Artiﬁcial binding proteins derived from small protein
domain scaffolds represent a valuable non-immunoglobulin
alternative for the construction of novel bio-sensing devices.
Engineered small, stable, robust, and soluble proteins with a
sufﬁcient thermal and hydrodynamic stability and without
disulphide bonds can be produced in a mass amount in
bacteria and easily modiﬁed by gene-fusion approaches. In
addition, they are amenable to rational improvement or
ab initio design and suitable for high-throughput selection
and diagnostic procedures (Gilbreth and Koide, 2012).
Recently we have demonstrated that a high-complex
combinatorial library derived from three-helix bundle of
albumin-binding domain (ABD) of streptococcal protein G
can be used for development of sub-to-nanomolar afﬁnity
binders of human interferon gamma (Ahmad et al., 2012) or
for novel IL-23 receptor antagonists with a promising anti-
inﬂammatory potential (Kuchar et al., 2014). Therefore, we
used this ABD scaffold-derived library to generate unique
binders of human PSP94. In combination with ﬁve cam-
paigns of ribosome display selection we generated a col-
lection of 35 PSP94-binding clones called PAB binders,
representing 29 unique sequence variants (Fig. 1A). These
variants in the form of fusion proteins, carrying 46 amino acid
residue-long ABD sequence linked to a helical 305 amino
acid TolA spacer protein with an installed C-terminal AviTag
consensus, were further characterized. PAB clones were
tested for the production of bacterial proteins after transfor-
mation of E. coli host cells and protein production in cell
lysates. After the veriﬁcation of binding function in ELISA in
combination with Western blot analysis, we selected most
promising candidates for more detailed characterization.
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Figure 1. Generation of PAB variants and their binding to recombinant HisTag-PSP94. (A) Similarity tree of polypeptide
sequences of the selected PAB binders. Analysis of a collection of 35 PAB binders obtained by ribosome display selection identiﬁed
29 unique sequence variants. For the analysis, randomized sequences between residues 20 and 46 were compared, as the
N-terminal amino acid positions 1–19 were non-mutated. The sequence of the parental ABD wild-type domain (●) was used as a root
of the tree. PAB variants selected for more detailed analysis are highlighted as triangles. (B) Binding of PAB variants to recombinant
HisTag-PSP94 assessed by ELISA. Serially-diluted PAB variants in the form of biotinylated HisTag-PAB-TolA-AviTag fusion proteins
were applied to a Polysorp microtiter plate coated with 10 μg/mL of recombinant HisTag-PSP94. WT-ABD indicates the parental wild-
type ABD-TolA-AviTag protein as a non-mutated control with the natural afﬁnity to HSA. The binding was detected by Streptavidin-
HRP conjugate. The error bars represent the standard deviation from the three measurements. (C) The binding afﬁnity of PAB
variants to the ﬂuorescently-labeled recombinant HisTag-PSP94 measured by microscale thermophoresis. Thermophoresis + T-jump
data shown as binding curves were evaluated by a NanoTemper software and calculated Kd values for PAB036, PAB046, and PAB50
variants were 40 ± 6 nmol/L, 49 ± 10 nmol/L, and 10 ± 3 nmol/L, respectively.
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Puriﬁed recombinant proteins of these PAB variants con-
ﬁrmed binding to immobilized His-PSP94 bacterial protein in
ELISA using detection with streptavidin-HRP conjugate
(Fig. 1B). We also veriﬁed that these selected protein vari-
ants do not substantially bind to coated BSA protein (data
not shown). To further conﬁrm that these PAB clones bind to
human PSP94 protein, we used another ELISA sandwich
layout in which in vivo biotinylated PAB clones were immo-
bilized to a coated streptavidin and binding of His-PSP94
was detected by anti-PSP94 antibody followed by a sec-
ondary IgG-HRP conjugate (results not shown).
To estimate the binding afﬁnity of the particular PAB
variants in solution, we used microscale thermophoresis
(MST) with a ﬂuorescently-labelled HisTag-PSP94 and
measured interactions with PAB036, PAB046, and PAB050
variants. In the Fig. 1C, binding curves obtained for all
selected PAB variants are shown, representing one of the
performed experiments. Using a commercial software, Kd
constants measured for all three PAB variants were esti-
mated to be 40 ± 6 nmol/L and 72 ± 25 for PAB036, 49 ± 10
nmol/L for PAB046, and 10 ± 3, 12 ± 3 and 21 ± 8 nmol/L (an
average value 14 nmol/L) for PAB050.
To corroborate whether PAB binders are capable of
binding to a native human target, we used LNCaP prostate
cancer cell line formerly described to secrete and cell-sur-
face express the PSP94 protein (Yang et al., 1998). To verify
this expected positivity, we used ﬂow cytometry to assay the
binding of two monoclonal and one polyclonal anti-PSP94
antibodies. As demonstrated in the Fig. 2A, all three anti-
PSP94 antibodies substantially bind to LNCaP cells while
the presence of the only secondary Cy-5-conjugated IgGs
remains to be negative. Statistical signiﬁcance of the positive
binding in comparison to the binding of the corresponding
secondary antibody only was veriﬁed by ANOVA and is
shown by asterisks. This result suggests that LNCaP cells
capture a part of the secreted PSP94 by an autologous
membrane receptor and can be, therefore, used for the
investigation of binding of PAB clones to the membrane-
bound PSP94. The possibility of the attachment of the
PSP94 to cell surface via interactions with a membrane
receptor has been already suggested (Annabi et al., 2006).
Results of binding of all used anti-PSP94 antibodies to cell
surface-bound PSP94 were further supported by intracellular
binding of these antibodies to LNCaP cells with permeabi-
lized membranes (results not shown). In the further experi-
ment, in vivo biotinylated PAB variants in the form of PAB-
TolA-AviTag fusion proteins were tested by ﬂow cytometry for
the ability to bind to PSP94-expressing LNCaP cells. The
ABD-wild-type protein corresponding to the parental non-
randomized ABD scaffold was used as a control to exclude
the possibility that non-randomized residues of the ABD
bundle could mediate high-afﬁnity interactions with prostate
cancer cells. In addition, presence of TolA fusion moiety,
identical between PAB variants and the ABD wild-type con-
trol, should exclude that ABD-unrelated TolA sequences
mediate or substantially contribute to cell-surface binding. As
demonstrated in the Fig. 2B, several PAB variants bind to
LNCaP cells, as detected by streptavidin-PE conjugate.
Statistical signiﬁcance of binding for each PAB variant
compared to the binding of parental wild-type ABD-TolA
control is provided by ANOVA and shown by asterisks. We
also investigated binding of PAB clones to permeabilized
LNCaP cells and results are in correlation with intact cells
staining (data not shown). Interestingly, PAB036 variant,
binding well to the bacterial PSP94 in ELISA, and substan-
tially also to the intracellular LNCaP cell product (not shown),
exhibited weaker cell-membrane binding compared to the
other PAB variants. It is possible that this clone recognizes a
different binding surface of the PSP94 in comparison to the
other binders and that this membrane PSP94, bound in an
oriented way to its cognate cell-surface receptor, is sterically
hindered and, thus, partially unapproachable for a full
PAB036 recognition. This is supported by a strong binding in
the case of a free accessible PSP94 (data not shown).
Based on the result of this binding assay, we selected
PAB036, PAB046, and PAB050 variants as the most
promising candidates for further characterization. The amino
acid sequences between residues 20 and 46 of these three
variants are as follows: PAB036: WYKNGINPAHRVRWVK-
GRIDAILARLP; PAB046: RYKNAINRAPAVWWVKRLIDAI-
LAALP; PAB050: LYKNHINTAWRVAAVKRAIDLILASLP, all
presented with the indicated positions of the 11 randomized
residues. Parental non-randomized WT-ABD full-length
sequence (46 amino acids of the full ABD scaffold) is
LAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDE
ILAALP with the marked mutable positions.
To verify whether recombinant bacterial human PSP94
competes with cell-bound PSP94, we performed cell-surface
competition binding assay in which PAB036, PAB046, and
PAB050 variants were mixed with an increasing concentra-
tion of the recombinant PSP94 protein and were left bound to
LNCaP cells for 30 min. The results of repeated experiments
shown in the Fig. 2C indicate that increasing concentrations
of the PSP94 protein inhibited binding of the PAB046 and
PAB050 variants to the cells. While the concentration 20 µg/mL
decreased binding of both these PAB proteins only by
5%–10%, concentration of 100 µg/mL inhibited this binding
substantially by 35% for PAB046 and by 74% for PAB050.
Contrary that, PAB036 variant did not exhibit any inhibitory
effect. Statistical evaluation by ANOVA was performed and
indicated by asterisks.
As an important proof of speciﬁcity of PAB binders, we
performed cell-surface competition binding assay using
LNCaP cells. We ﬁrst tested whether monoclonal antibody
YPSP-1 inhibits binding of PAB variants to LNCaP cells by
ﬂow cytometry. Our data demonstrated that this monoclonal
antibody did not compete with PAB036, PAB046, and
PAB050 variants for binding to LNCaP cells (data not
shown), suggesting that an interacting epitope differs from
those recognized by the particular PAB binders. We also
tested the ability of polyclonal antibody sc-68920 to inhibit
binding of PAB variants to the same cells and found that this
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antibody is able to suppress the PAB binding. We used it,
therefore, in cell-surface competition binding assay to
demonstrate the speciﬁcity of used PAB binders for cell-
bound PSP94 recognition on LNCaP cells. As shown in
Fig. 2D, a dose of 4 micrograms of sc-68920 suppressed the
binding of PAB046 and PAB050 by 30% compared to the
control non-inhibited PAB variants (100%) and this decrease
is statistically signiﬁcant as veriﬁed by ANOVA (indicated by
asterisks). On the other hand, inhibition of PAB036 binding
was only about 15%. ABD-WT-TolA protein was used as a
non-inhibiting ABD control in this ﬂow cytometry test. To
investigate what is the impact of ABD scaffold randomization
on PAB binder’s stability, we measured thermal stability of
PAB036, PAB046, and PAB050 variants using thermal shift
assay (TSA). Temperature melting points (Tm) measured in
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PAB036, 48.5°C for PAB046, and 46.0°C for PAB050
(Fig. 2E and 2F). Tm value for parental non-randomized wild-
type ABD is 58.0°C. These data indicate that particular
mutations in each of variants can strongly affect the protein
stability. While in the case of PAB036 variant the amino acid
alterations slightly improved the original scaffold stability,
thermal stability of PAB046 as well as PAB050 was signiﬁ-
cantly decreased.
Collectively, we present the generation and characteri-
zation of unique protein binders of human prostate cancer
oncomarker that can be useful as alternatives to monoclonal
antibodies for detection of MSMB in studies of fertilization
and, with possible modiﬁcations using gene-fusion or afﬁnity
maturation approaches, they could serve as novel capture
proteins for improved prostate cancer diagnostics.
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